Speciality: Oncology
Description:
Welcome, viewers! In this insightful presentation, Dr. Shailesh Bondarde, a renowned oncologist, delves into the transformative role of CDK4/6 inhibitors in managing hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (aBC). Drawing from robust clinical trial data and real-world evidence, Dr. Bondarde highlights how these targeted therapies have reshaped treatment paradigms, offering hope and extended survival to countless patients.
Clinical trials have consistently demonstrated that CDK4/6 inhibitors, when combined with endocrine therapy, significantly improve progression-free survival (PFS) and overall survival (OS) in HR+/HER2- aBC. Landmark studies such as PALOMA, MONARCH, and MONALEESA have shown reduced disease progression by nearly 50% and extended median OS by years, even in high-risk subgroups. These agents also exhibit manageable toxicity profiles, enabling prolonged treatment adherence. Beyond trials, real-world evidence corroborates these benefits, with observational studies reporting improved quality of life, delayed chemotherapy use, and enhanced survival rates across diverse populations, including older adults and those with visceral metastases.
As we conclude, Dr. Bondarde emphasizes integrating CDK4/6 inhibitors into standard care while addressing challenges like accessibility and cost. Their efficacy in controlled trials and real-world practice underscores their value as a cornerstone of HR+/HER2- aBC management. Stay tuned to explore more groundbreaking insights in oncology, and don’t forget to subscribe for updates on upcoming videos. Thank you for watching!
See More Webinars @ Hidoc Webinars
1.
Three out of ten breast cancers detected between screenings, study finds
2.
Second Malignancy Risk With CAR T-Cell Therapy on Par With Other Treatments
3.
Where Did This Very Painful Gluteal Mass Come From?
4.
As compared to proton therapy, proton therapy is very effective in treating esophageal cancer.
5.
Rucaparib Delays Next Lines of Therapy in Ovarian Cancer
1.
Exploring The Science Of Hematopoietic Stem Cell Transplantation: What You Need To Know
2.
Optimizing Melanoma Treatment: Strategies in Diagnosis, Clinical Research, and Physician Training
3.
Unleashing the Oncolytic Arsenal: Talimogene Laherparepvec Monotherapy – A Targeted Cancer Immunotherapy Treatment
4.
Clonal Hematopoiesis Dynamics and Future Hematologic Outcomes
5.
Understanding Mesenteric Masses: Symptoms, Diagnosis, and Treatment Options
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Incidence of Lung Cancer- An Overview to Understand ALK Rearranged NSCLC
2.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases - Part II
3.
Evidence-Based Oncology
4.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
5.
Preventing Immune Effector Cell-Associated Neurotoxicity Through Early Neurovascular Biomarker Surveillance
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation